October 7, 2009 — Patients with brain metastases who were treated with whole-brain radiation therapy in addition to stereotactic radiosurgery were found to be at greater risk for cognitive decline, ...

Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial Authors retain all rights in ...

Paris (France), November, 30 th 2023 – NH TherAguix a Phase 2 biotech company developing AGuIX®, an innovative nanodrug to improve cancer treatment by radiotherapy, announces the completion of ...

For Multiple Brain Mets Patients, Significantly Less Healthy Brain Exposed with Dedicated Radiosurgery Devices Compared to Multi-Purpose Radiotherapy Systems ZAP Surgical Systems, Inc., developer of ...

People who experience side effects from cranial radiation therapy may recover full neurocognitive function within months. (HealthDay News) — Many patients with brain metastases who experience initial ...

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they ...

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates. Approximately 4 out of every 5 patients with SCLC ...

WASHINGTON, September 29, 2024 — A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according ...

Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network The study cohort included 27 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

The University of Cincinnati's Debanjan Bhattacharya is first author of new research published in Cancers that found the drug AM-101 improves the effectiveness and survival rate of radiation treatment ...